New daily pill orforglipron outperforms oral semaglutide in major weight-loss trial
In a major clinical trial, the once-daily pill orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide — the active ingredient in Ozempic. The drug requires no refrigeration and no special timing with meals, making it a more convenient alternative to injectable drugs such as Ozempic and Wegovy. It is also cheaper to manufacture, which could broaden global access.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!